SHH and neoplasm: The complexity of these interactions is highlighted by the fact that, despite increasing vascular normalization and drug delivery [72], targeting the SHH pathway to disrupt the stroma in PDAC accelerated tumor growth [78] and, unfortunately, failed in clinical trials, as detailed later [138].